RDX Bioscience, INC

RDX Bioscience, INC was paid $36.26M by Medicaid between Jan 2018 and May 2023, across 155 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 51% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#11 of 122

Median peer was paid$1.29M

This provider vs. median28×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	547,886	$6.09M
2019	783,795	$10.47M
2020	546,080	$8.84M
2021	646,803	$5.78M
2022	745,828	$4.47M
2023	144,378	$610K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	51%	155,105	82,175	$18.55M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	20%	310,114	155,473	$7.19M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	2.9%	19,159	13,568	$1.04M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.1%	15,965	11,227	$771K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.6%	14,288	7,452	$578K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.1%	7,352	5,361	$416K
83992		<1%	94,593	51,329	$322K
80354		<1%	98,662	53,610	$283K
80372		<1%	92,363	50,447	$257K
80338		<1%	76,954	43,226	$256K
80373		<1%	92,416	50,489	$256K
80357		<1%	91,796	49,478	$256K

143 more codes

80371		<1%	87,985	$255K
80369		<1%	75,121	$250K
80360		<1%	84,631	$245K
80368		<1%	76,537	$243K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	12,869	$233K
80323		<1%	93,291	$222K
80332		<1%	38,195	$209K
80355		<1%	70,822	$209K
80366		<1%	70,345	$203K
80346		<1%	97,899	$162K
80342		<1%	35,271	$156K
80348		<1%	96,539	$152K
80339		<1%	37,166	$146K
80356		<1%	98,239	$144K
80353		<1%	95,711	$143K
80349		<1%	89,499	$142K
80359		<1%	96,345	$141K
80324		<1%	47,528	$140K
80358		<1%	94,992	$138K
80361		<1%	87,602	$137K
80365		<1%	88,826	$136K
80363		<1%	92,175	$134K
80345		<1%	71,144	$123K
80367		<1%	87,375	$122K
80343		<1%	36,372	$111K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,621	$108K
80335		<1%	38,996	$96K
80325		<1%	48,185	$89K
86769		<1%	2,876	$85K
80333		<1%	38,739	$80K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	7,523	$80K
80061	Lipid panel	<1%	8,699	$56K
80053	Comprehensive metabolic panel	<1%	7,928	$55K
80340		<1%	35,936	$54K
84443	Thyroid stimulating hormone (TSH)	<1%	8,273	$53K
80350		<1%	52,918	$52K
80337		<1%	36,963	$46K
82607		<1%	6,773	$45K
86703		<1%	2,917	$37K
83970		<1%	2,679	$36K
82728		<1%	4,719	$34K
86803		<1%	2,862	$34K
82746		<1%	5,256	$33K
84480		<1%	5,397	$33K
83036	Hemoglobin; glycosylated (A1C)	<1%	7,552	$31K
80321		<1%	9,211	$31K
86480		<1%	866	$28K
86704		<1%	2,779	$25K
86706		<1%	2,835	$23K
84144		<1%	3,286	$21K
83001		<1%	3,299	$21K
82627		<1%	2,721	$20K
87340		<1%	2,833	$20K
84146		<1%	3,160	$20K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	2,510	$20K
86708		<1%	2,373	$20K
83002		<1%	3,301	$19K
84403		<1%	2,770	$18K
87486		<1%	1,991	$18K
87581		<1%	1,990	$17K
84270		<1%	2,634	$17K
83090		<1%	2,948	$15K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	7,918	$14K
86141		<1%	3,515	$14K
84436		<1%	5,366	$14K
87631		<1%	297	$14K
83540		<1%	4,865	$13K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	513	$12K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	513	$11K
83003		<1%	2,163	$11K
82553		<1%	2,885	$11K
86735		<1%	1,072	$11K
84311		<1%	4,335	$10K
84402		<1%	693	$9K
80050	General health panel	<1%	616	$9K
83735		<1%	3,464	$9K
84484		<1%	2,876	$8K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	221	$8K
86765		<1%	1,082	$8K
84479		<1%	3,604	$7K
82550		<1%	2,914	$7K
82652		<1%	419	$7K
82977		<1%	2,649	$7K
82570		<1%	4,330	$6K
84315		<1%	4,470	$6K
84100		<1%	3,402	$6K
85045		<1%	2,158	$6K
84550		<1%	3,544	$6K
84153		<1%	1,029	$6K
83690		<1%	2,703	$6K
83615		<1%	2,615	$5K
84439		<1%	1,314	$5K
82670		<1%	2,991	$5K
86780		<1%	574	$5K
83986		<1%	4,333	$4K
86762		<1%	1,125	$4K
84481		<1%	706	$3K
87522	Neg quan hep c or qual rna	<1%	153	$2K
80074		<1%	279	$2K
84702		<1%	246	$2K
81003		<1%	1,802	$1K
80336		<1%	2,244	$1K
87632		<1%	40	$1K
80364		<1%	2,688	$1K
84154		<1%	257	$1K
86705		<1%	1,953	$1K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	178	$1K
86431		<1%	392	$711.21
86709		<1%	2,112	$682.39
83550		<1%	70	$407.66
86060		<1%	266	$382.28
81025		<1%	144	$379.82
86038		<1%	233	$357.26
86787		<1%	117	$340.08
83525		<1%	230	$339.95
81001		<1%	248	$322.25
82947		<1%	597	$303.36
87086	Culture, bacterial; quantitative colony count, urine	<1%	99	$276.60
85652		<1%	315	$273.17
82043		<1%	149	$271.83
86592		<1%	1,234	$241.82
80076		<1%	639	$221.75
85014		<1%	230	$212.84
85018		<1%	230	$212.84
83655		<1%	34	$153.00
82533		<1%	12	$152.27
86304		<1%	13	$147.10
84075		<1%	27	$59.68
84478		<1%	15	$43.80
84295		<1%	16	$43.68
84132		<1%	418	$29.59
82465		<1%	20	$27.00
82310		<1%	31	$19.97
86160		<1%	12	$18.00
82374		<1%	29	$17.74
82565		<1%	28	$13.24
84520		<1%	29	$10.20
84155		<1%	27	$9.50
84460		<1%	14	$9.46
84450		<1%	14	$9.26
82247		<1%	15	$8.96
82040		<1%	15	$8.84
82435		<1%	17	$8.20

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLEYKIN, ERIC (OWNER)